Correlation of positron emission tomography and CT in evaluating pancreatic tumors: Technical and clinical implications

American Journal of Roentgenology

Volumn 181, Issue 2, 2003, Pages 387-393

  Kalra, Mannudeep K ^a   Maher, Michael M ^a   Boland, Giles W ^a   Saini, Sanjay ^a   Fischman, Alan J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CARBON; CARBON 11; DNA; DOPA; FLUORODEOXYGLUCOSE; FUROSEMIDE; GLUCOSE; GLUCOSE DERIVATIVE; GLUCOSE TRANSPORTER; HEXOSE PHOSPHATE; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; RNA; TRACER;

ANGIOGRAPHY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; ENDOCRINE TUMOR; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CYST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0041843882     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.181.2.1810387     Document Type: Review

References (56)

1. American Cancer Society. Cancer facts and figures 2002: year 2002 surveillance research from the American Cancer Society. Bethseda, MD: American Cancer Society, 2002
2. Kedra B, Popiela T, Sierzega M, Precht A. Prognostic factors of long-term survival after resective procedures for pancreatic cancer. Hepatogastroenterology 2001;48:1762-1766
3. Del Frate C, Zanardi R, Mortele K, et al. Advances in imaging for pancreatic disease. Curr Gastroenterol Rep 2002;4:140-148
4. Kopka L, Rogalla P, Hamm B. Multislice CT of the abdomen: current indications and future trends [in German]. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2002;174:273-282
5. Brizi MG, Natale L, Manfredi R, Sallustio G, Vecchioli A, Marano P. High resolution spiral computed tomography of the pancreas. Rays 2001;26:111-115
6. Murcia NM, Jeffrey RB, Beaulieu CF, King CPL, Rubin GD. Multidetector CT of the pancreas and bile duct system: value of curved planar reformations. AJR 2001;176:689-693
7. Horton KM, Fishman EK, Multidetector CT angiography of pancreatic carcinoma. I. Evaluation of arterial involvement. AJR 2002;178:827-831
8. Horton KM, Fishman EK. Multidetector CT angiography of pancreatic carcinoma. II. Evaluation of venous involvement. AJR 2002;178:833-836
9. Kasperk RK, Riesener KP, Wilms K, Schumpelick V. Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon's view. World J Surg 2001;25:1134-1139
10. O'Malley ME, Boland GW, Wood BJ, Fernandez-del Castillo C, Warshaw AL. Mueller PR. Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical CT. AJR 1999;173:1513-1518
11. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am 2001;39:883-917
12. Fahey FH. Positron emission tomography instrumentation. Radiol Clin North Am 2001;39:919-929
13. Zanzi I, Robeson W, Vinciguerra V. Positron emission tomography (PET) imaging in patients with carcinoma of the pancreas. In: Proceedings of American Society of Clinical Oncology. Alexandria, VA: American Society of Clinical Oncology, 1990;9:A434
14. Bares R, Klever P, Hellwig D, et al. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results. Nucl Med Commun 1993;14:596-601
15. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487-490
16. Alazraki N. Imaging of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastrointest Surg 2002;6:136-138
17. Ak I, Blokland JA, Pauwels EK, Stokkel MP. The clinical value of 18F-FDG detection with a dual-head coincidence camera. Eur J Nucl Med 2001;28:763-778
18. Zhang H, Tian M, Oriuchi N, Higuchi T, Tanada S, Endo K. Oncological diagnosis using positron coincidence gamma camera with fluorodeoxyglucose in comparison with dedicated PET. Br J Radiol 2002;75:409-416
19. Balci NC, Semelka RC. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Eur J Radiol 2001;38:105-112
20. Ho CL, Dehdashti F, Griffeth LK, Buse PE, Balfe DM, Siegel BA. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr 1996;20:363-369
21. Benyounes H, Smith FW, Campbell C, et al. Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma. Nucl Med Commun 1995;16:575-580
22. Inagaki H, Kato T, Tadokoro M, et al. Interactive fusion of three-dimensional images of upper abdominal CT and FDG PET with no body surface markers. Radiat Med 1999;17:155-163
23. Townsend DW, Cherry SR. Combining anatomy and function: the path to true image fusion. Eur Radiol 2001;11:1968-1974
24. Beyer T, Townsend DW, Blodgett TM. Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med 2002;46:24-34
25. Zimny M, Buell U. 18 FDG-positron emission tomography in pancreatic cancer. Ann Oncol 1999;10[suppl 4]:28-32
26. Jadvar H, Fischman AJ. Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 2001;26:254-259
27. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variations of 18-fluorodeoxyglucose positron emission tomography scanning: potential for errors in interpretation. Semin Nucl Med 1996;26:308-314
28. Del Maschio A, Vanzulli A, Sironi S, et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with Ca 19-9 assessment, US, CT, and CT-guided fine needle biopsy. Radiology 1991;178:95-99
29. Inokuma T, Okamoto T, Ogami T, et al. Diagnosis of pancreatic cancer with FDG-PET: comparison with CT, US and endoscopic US. (abstr) Gut 1996;39[suppl 3]:12
30. Berberat P, Friess H, Kashiwagi M, Beger HG, Buchler MW. Diagnosis and staging of pancreatic cancer by positron emission tomography. World J Surg 1999;23:882-887
31. Bares R, Klever P, Hauptmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994;192:79-86
32. Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2(18F)-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995;36:771-777
33. van Heertum RL, Fawwaz RA. The role of nuclear medicine in the evaluation of pancreatic disease. Surg Clin North Am 2001;81:345-358
34. Zimny M, Bares R, Fass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997;24:678-682
35. Bares R, Dohmen BM, Cremerius U, Fass J, Teusch M, Bull U. Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma [in German]. Radiologe 1996;36:435-440
36. Frohlich A, Diederichs CG, Staib L, Vogel J. Beger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999;40:250-255
37. Nakata B, Nishimura S, Ishikawa T, et al. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 2001;19:53-58
38. Zimny M, Fass J, Bares R, et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 2000;8:883-888
39. Nitzsche EU, Hoegerle S, Mix M, et al. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med 2002;29:237-242
40. Koyama K, Okamura T, Kawabe J, et al. Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001;15:217-224
41. Nakamoto Y, Higashi T, Sakahara H, et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547-2554
42. Rose DM, Delbeke D, Beauchamp RD, et al. 18 Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999;229:729-737
43. Franke C, Klapdor R, Meyerhoff K, Schauman M. 18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer Res 1999;19:2437-2442
44. Higashi T, Sakahara H, Torizuka T, et al. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med 1999;40:1424-1433
45. Nakamoto Y, Saga T, Ishimori T, et al. FDG-PET of autoimmune-related pancreatitis: preliminary results. Eur J Nucl Med 2000;27:1835-1838
46. Rajput A, Stellato TA, Faulhaber PF, Vesselle HJ, Miraldi F. The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease. Surgery 1998;124:793-797
47. Keogan MT, Tyler D, Clark L, et al. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR 1998;171:1565-1570
48. Slater JB, Miller DW, Slater JD, Slater JM. Integration of PET in radiation medicine. Clin Pos Imag 1999;2:236
49. Jensen RT, Norton JA. Endocrine neoplasm of the pancreas. In: Yamada T, Alpers DH, Powell DW, Silverstein FE, eds. Textbook of gastroenterology, vol. 2. Philadelphia: Lippincott, 1995:2131-2160
50. Bombardieri E. Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumors. Ann Oncol 2001;12[suppl 2]:51-61
51. Nakamoto Y, Higashi T, Sakahara H, et al. Evaluation of pancreatic islet cell tumors by fluorine-18 fluorodeoxyglucose positron emission tomography: comparison with other modalities. Clin Nucl Med 2000;25:115-119
52. Ahlstrom H, Eriksson B, Bergstrom M, Bjurling P, Langstrom B, Oberg K. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995;195:333-337
53. Sperti C, Pasquali C, Chierichetti F, Liessi G, Ferlin G, Pedrazzoli S. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg 2001;234:675-680
54. Zimny M, Schumpelick V. Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions. Chirurg 2001;72:989-994
55. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999;40:1784-1791
56. Kato T, Fukatsu H, Ito K, et al. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem Eur J Nucl Med 1995;22:32-39